Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study.
Menogaril, a semisynthetic anthracycline antibiotic, was administered to patients with metastatic adenocarcinoma of the prostate. Forty-five patients with measurable disease and 45 patients with evaluable disease received 150-200 mg/m2 over 1 hour every 28 days. There were three partial responses (PR) among 87 patients evaluable for response. Myelosuppression was dose limiting. There were two deaths related to leukepenia. Other toxicities included phlebitis, alopecia, nausea and vomiting. One patient developed acute nonlymphocytic leukemia. Menogaril at these doses and schedule is toxic and has no significant antitumor activity in metastatic adenocarcinoma of the prostate.
University of Kansas Medical Center, Kansas City.
S A
SA
Taylor
B A
BA
Blumenstein
R L
RL
Stephens
E D
ED
Crawford
B
B
Pistone
J B
JB
Hill
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006321:Heart / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D017290:Menogaril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D006454:Hemoglobins; D017290:Menogaril